Monte Rosa Therapeutics, Inc. (GLUE) stock
GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07+0.00 (0.00%)
Close on Nov 18, 2026Market cap $773.79MP/E –Yield –
Monte Rosa Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Monte Rosa Therapeutics's pe ratio was 82.1× on Jan 30, 2026.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jan 30, 2026 | 82.1× | +19.4 |
| 2025 | Dec 31, 2025 | 62.7× | – |
See a number that looks wrong?